Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blast of argon plasma wipe out cervical precancer without surgery?

NCT ID NCT07730645

Cure Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The main goal is to see if the plasma treatment leads to complete healing of the abnormal tissue after six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-thermal argon plasma devitalization (LtAPD) applied via a device
What this could lead to
If effective, this one-time outpatient procedure could offer a non-surgical way to clear high-grade cervical precancer, potentially reducing the need for more invasive treatments.
What could go wrong
This is a mid-sized trial comparing the plasma treatment to a sham procedure and active surveillance. The effect may be modest, and long-term outcomes beyond 6 months are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 264 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex * Age 18 - 40 years at the time of signing the informed consent * Histologically confirmed CIN 2 * Full visibility of the entire transformation zone (Type 1 or Type 2) and entire lesion in colposcopy * Ability to understand the nature of the clinical investigation and voluntarily signs the informed consent document prior to any study-related procedures Exclusion Criteria: * Histologically confirmed CIN other than CIN 2, or indication of (micro-) invasive cervical disease * CIN lesions extending to the vaginal vault or suspicion of endocervical disease * Current pregnancy or planned pregnancy within the next 6 months * Presence of severe local inflammation or active infection * Presence of a severe cardiovascular, neurological, psychiatric, endocrine, or hematological disease, immunocompromised condition or malignant tumor of any origin, as judged by the investigator * Participation in an interfering clinical study, as judged by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical intraepithelial neoplasia grade 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical intraepithelial neoplasia grade 2/3 cervical squamous intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical intraepithelial neoplasia grade 2 Cervical intraepithelial neoplasia grade 2 (CIN2) CIN2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Tuebingen, Department of Women's Health

    Tübingen, Baden-Wurttemberg, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.